← Leaderboards
Jordan S Pober
Yale University
$30,894,969
Attributed
$41,218,855
Total exposure
24
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,129,057 · 25
By mechanism
R01$31,734,339 · 10
P01$20,769,270 · 4
R21$2,543,459 · 6
U01$2,193,773 · 1
R56$709,250 · 2
R37$663,579 · 1
Top collaborators
- W Mark Saltzman26 shared
- Thomas David Manes9 shared
- George Tellides9 shared
- Alfred Lm Bothwell4 shared
- Martin S Kluger4 shared
- Sanjay Kulkarni2 shared
Others in their field
Top investigators on “Endothelial Cells”
- Keri Hammel · The Emmes Company, Llc$41,089,609
- Martin Friedlander · Scripps Research Institute$38,298,285
- Michael Simons · Yale University$37,176,481
- Ajit P Varki · University Of California San Diego$34,208,221
- Joseph C Wu · Stanford University$33,648,524
- Jan E Schnitzer · Sidney Kimmel Cancer Center$31,414,677
Research focus
Endothelial CellsMediatingCellsResponseBlood VesselsIn VivoIn VitroCytokineProteinsT-LymphocyteSignal TransductionTransplantationImmunodeficient MouseInjuryTissuesAllogenicAllograftingBaseOrganHuman TissuePathway InteractionsAntigensCell TypeGrant
Grant awards (118)
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$678,206
R01 · FY2025 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium$642,639
R01 · FY2025 · AI · contact PI
Mechanisms and consequences of antigen-dependent T cell homing for adoptive immunotherapies$418,750
R01 · FY2025 · AI · contact PI
Targeting complement-induced IL-15 trans-presentation by human endothelial cells$203,094
R21 · FY2025 · AI · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell_Transplantation$36,814
R01 · FY2025 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$678,206
R01 · FY2024 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium$642,639
R01 · FY2024 · AI · contact PI
Mechanisms and Ex Vivo Repair of Cold-Storage Injury in Human Kidney Allografts$489,367
R01 · FY2024 · DK · contact PI
Mechanisms and consequences of antigen-dependent T cell homing for adoptive immunotherapies$418,750
R01 · FY2024 · AI · contact PI
Targeting complement-induced IL-15 trans-presentation by human endothelial cells$251,250
R21 · FY2024 · AI · contact PI
Mechanisms and Ex Vivo Repair of Cold-Storage Injury in Human Kidney Allografts$509,756
R01 · FY2023 · DK · contact PI
Mechanisms and consequences of antigen-dependent T cell homing for adoptive immunotherapies$418,750
R01 · FY2023 · AI · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium$418,250
R56 · FY2023 · AI · contact PI
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts$209,375
R21 · FY2022 · AI · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$489,354
U01 · FY2021 · AI · contact PI
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts$251,250
R21 · FY2021 · AI · contact PI
Human B cell infiltration into allografts: mechanisms and molecules$209,375
R21 · FY2021 · AI · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$29,419
U01 · FY2021 · AI · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2020 · AI · contact PI
Stress Signaling Pathways Linking Endothelial Injury to Graft Arteriosclerosis$418,750
R01 · FY2020 · HL · contact PI
Human B cell infiltration into allografts: mechanisms and molecules$251,250
R21 · FY2020 · AI · contact PI
Human Vascular Cell Functions in Acute Allograft Rejection$505,517
R01 · FY2019 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2019 · AI · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$401,802
R01 · FY2019 · HL
Combined Human Myeloid and Lymphoid Engraftment in MISTRG Mice for Transplantation Research$209,375
R21 · FY2019 · AI · contact PI
Human Vascular Cell Functions in Acute Allograft Rejection$512,026
R01 · FY2018 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2018 · AI · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$401,802
R01 · FY2018 · HL
Combined Human Myeloid and Lymphoid Engraftment in MISTRG Mice for Transplantation Research$251,250
R21 · FY2018 · AI · contact PI
Human Vascular Cell Functions in Acute Allograft Rejection$518,346
R01 · FY2017 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2017 · AI · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$401,802
R01 · FY2017 · HL
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$372,359
R01 · FY2017 · HL
Human Vascular Cell Functions in Acute Allograft Rejection$512,075
R01 · FY2016 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$401,802
R01 · FY2016 · HL
Targeting Nanoparticles for Drug Delivery to Renal Graft Endothelium during Ex Vivo Normothermic Perfusion$251,250
R21 · FY2016 · AI
Presentation of Alloantigen by Human Vascular Cells$507,862
R01 · FY2015 · HL · contact PI
Proteins of the Endothelial Cell Surface$463,914
R01 · FY2015 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$399,840
R01 · FY2015 · HL
Regulating Anti-Endothelial T Cell Responses in Graft Arteriosclerosis$610,733
R01 · FY2014 · HL · contact PI
Presentation of Alloantigen by Human Vascular Cells$505,284
R01 · FY2014 · HL · contact PI
Proteins of the Endothelial Cell Surface$459,412
R01 · FY2014 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$397,811
R01 · FY2014 · HL
Regulating Anti-Endothelial T Cell Responses in Graft Arteriosclerosis$595,628
R01 · FY2013 · HL · contact PI
Presentation of Alloantigen by Human Vascular Cells$489,987
R01 · FY2013 · HL · contact PI
Proteins of the Endothelial Cell Surface$442,888
R01 · FY2013 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$386,443
R01 · FY2013 · HL
Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection$291,000
R56 · FY2013 · AI
Regulating Anti-Endothelial T Cell Responses in Graft Arteriosclerosis$626,288
R01 · FY2012 · HL · contact PI
Presentation of Alloantigen by Human Vascular Cells$513,144
R01 · FY2012 · HL · contact PI
Proteins of the Endothelial Cell Surface$508,345
R01 · FY2012 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$404,758
R01 · FY2012 · HL
Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self-Assembly$249,063
R21 · FY2012 · HL
Regulating Anti-Endothelial T Cell Responses in Graft Arteriosclerosis$626,947
R01 · FY2011 · HL · contact PI
Presentation of Alloantigen by Human Vascular Cells$512,499
R01 · FY2011 · HL · contact PI
Proteins of the Endothelial Cell Surface$470,421
R01 · FY2011 · HL · contact PI
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation$403,586
R01 · FY2011 · HL
Controlled Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self$206,927
R21 · FY2011 · HL
Chronic DTH and IFN-gamma in Human Graft Arteriosclerosis$2,360,957
P01 · FY2010 · HL · contact PI
Alloimmunity to Progenitor Cell-Derived Human Vascular Cells$599,458
R01 · FY2010 · HL · contact PI
Proteins of the Endothelial Cell Surface$458,391
R01 · FY2010 · HL · contact PI
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells$452,504
P01 · FY2010 · HL · contact PI
Administration$71,590
P01 · FY2010 · HL · contact PI
Chronic DTH and IFN-gamma in Human Graft Arteriosclerosis$2,301,198
P01 · FY2009 · HL · contact PI
Alloimmunity to Progenitor Cell-Derived Human Vascular Cells$596,043
R01 · FY2009 · HL · contact PI
Proteins of the Endothelial Cell Surface$455,143
R01 · FY2009 · HL · contact PI
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells$442,714
P01 · FY2009 · HL · contact PI
Human CTL-Mediated Injury of Graft Endothelial Cells$433,669
R01 · FY2009 · HL · contact PI
Administration$70,052
P01 · FY2009 · HL · contact PI
Chronic DTH and IFN-gamma in Human Graft Arteriosclerosis$2,220,189
P01 · FY2008 · HL · contact PI
Alloimmunity to Progenitor Cell-Derived Human Vascular Cells$569,240
R01 · FY2008 · HL · contact PI
Proteins of the Endothelial Cell Surface$444,016
R01 · FY2008 · HL · contact PI
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells$424,535
P01 · FY2008 · HL · contact PI
Human CTL-Mediated Injury of Graft Endothelial Cells$414,710
R01 · FY2008 · HL · contact PI
SCID Mouse: Human Xenograft Core$112,847
P30 · FY2008 · AR · contact PI
Administration$67,199
P01 · FY2008 · HL · contact PI
Chronic DTH and IFN-gamma in Human Graft Arteriosclerosis$2,201,842
P01 · FY2007 · HL · contact PI
Alloimmunity to Progenitor Cell-Derived Human Vascular Cells$566,115
R01 · FY2007 · HL · contact PI
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells$427,793
P01 · FY2007 · HL · contact PI
Human CTL-Mediated Injury of Graft Endothelial Cells$412,978
R01 · FY2007 · HL · contact PI
SCID Mouse : Human Xenograft Core$98,430
P30 · FY2007 · AR · contact PI
Administration$40,576
P01 · FY2007 · HL · contact PI
Chronic DTH and IFN-gamma in Human Graft Arteriosclerosis$2,233,335
P01 · FY2006 · HL · contact PI
Alloimmunity to Progenitor Cell-Derived Human Vascular Cells$568,280
R01 · FY2006 · HL · contact PI
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells$423,564
P01 · FY2006 · HL · contact PI
Human CTL-Mediated Injury of Graft Endothelial Cells$415,115
R01 · FY2006 · HL · contact PI
Proteins of the Endothelial Cell Surface$399,144
R01 · FY2006 · HL · contact PI
Core B - SCID Mouse : Human Xenograft Core (Jordan Pober, MD/PhDP.I.)$101,370
P30 · FY2006 · AR · contact PI
Administration$67,150
P01 · FY2006 · HL · contact PI
Chronic DTH and IFN-gamma in Human Graft Arterioscleros*$1,439,224
P01 · FY2005 · HL
ENDOTHELIAL MODIFICATIONS THAT REDUCE T CELL ACTIVATION$516,722
R01 · FY2005 · HL
Human CTL-Mediated Injury of Graft Endothelial Cells$413,088
R01 · FY2005 · HL
Proteins of the Endothelial Cell Surface$408,750
R01 · FY2005 · HL
Chronic DTH in human GA$193,924
P01 · FY2005 · HL
Core B - SCID Mouse : Human Xenograft Core (Jordan Pober, MD/PhDP.I.)$101,370
P30 · FY2005 · AR
Chronic DTH and IFN-gamma in Human Graft Arterioscleros*$1,317,930
P01 · FY2004 · HL
ENDOTHELIAL MODIFICATIONS THAT REDUCE T CELL ACTIVATION$502,969
R01 · FY2004 · HL
Proteins of the Endothelial Cell Surface$408,750
R01 · FY2004 · HL
HUMAN CTL-MEDIATED INJURY OF GRAFT ENDOTHELIAL CELLS$375,535
R01 · FY2004 · HL
Core B - SCID Mouse : Human Xenograft Core (Jordan Pober, MD/PhDP.I.)$101,370
P30 · FY2004 · AR
Chronic DTH and IFN-gamma in Human Graft Arterioscleros*$81,750
P01 · FY2004 · HL
Chronic DTH and IFN-gamma in Human Graft Arterioscleros*$1,279,544
P01 · FY2003 · HL
ENDOTHELIAL MODIFICATIONS THAT REDUCE T CELL ACTIVATION$489,614
R01 · FY2003 · HL
Proteins of the Endothelial Cell Surface$408,750
R01 · FY2003 · HL
HUMAN CTL-MEDIATED INJURY OF GRAFT ENDOTHELIAL CELLS$364,804
R01 · FY2003 · HL
Chronic DTH and IFN-gamma in Human Graft Arterioscleros*$1,242,272
P01 · FY2002 · HL
ENDOTHELIAL MODIFICATIONS THAT REDUCE T CELL ACTIVATION$476,650
R01 · FY2002 · HL
Proteins of the Endothelial Cell Surface$408,750
R01 · FY2002 · HL
HUMAN CTL-MEDIATED INJURY OF GRAFT ENDOTHELIAL CELLS$354,179
R01 · FY2002 · HL
Chronic DTH in human GA$177,467
P01 · FY2002 · HL
Chronic DTH and IFN-gamma in Human Graft Arterioscleros*$1,231,961
P01 · FY2001 · HL
ENDOTHELIAL MODIFICATIONS THAT REDUCE T CELL ACTIVATION$464,064
R01 · FY2001 · HL
HUMAN CTL-MEDIATED INJURY OF GRAFT ENDOTHELIAL CELLS$343,865
R01 · FY2001 · HL
PROTEINS OF THE ENDOTHELIAL CELL SURFACE$335,474
R37 · FY2001 · HL
Chronic DTH in human GA$0
P01 · FY2001 · HL
ENDOTHELIAL MODIFICATIONS THAT REDUCE T CELL ACTIVATION$425,750
R01 · FY2000 · HL
HUMAN CTL-MEDIATED INJURY OF GRAFT ENDOTHELIAL CELLS$333,849
R01 · FY2000 · HL
PROTEINS OF THE ENDOTHELIAL CELL SURFACE$328,105
R37 · FY2000 · HL